Track 2 Speakers
Kristopher Bough, Ph.D.
Kristopher Bough, Ph.D., is a neuroscientist and pharmacologist with a background in ‘top-down’ translation. During his career in academia, Bough developed an animal model for an unexplored therapy of epilepsy and, subsequently, employed a variety of approaches (e.g., electrophysiology, microarrays, electron microscopy) to investigate its underlying mechanisms of action. In 2005, he began his career in the government within the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research, where he served as a pharmacologist before moving to the NIH National Institute on Drug Abuse’s Division of Pharmacotherapies and Medical Consequences in 2008. There he oversaw a clinical portfolio of Phase I / II clinical trials, primarily aimed at the development of novel treatments for nicotine- and cocaine addiction. Since joining NIH, Bough has helped manage NIDA’s SBIR program on both the divisional- and institute-level and served as an annual reviewer for the Commercialization Assistance Program. Bough’s presentation will introduce the various considerations required to develop a drug or device and offer general strategies for circumventing these hurdles.
Juliana Cyril, Ph.D., received her bachelor’s degree from the University of California, Berkeley. Prior to pursuing graduate studies, Cyril worked for two years as a research associate in the Institute for Health and Aging at the University of California, San Francisco. In 1994, she received her Master of Public Health from the University of Washington and, in 2001, received her Ph.D. in Public Health from Johns Hopkins University. She joined the U.S. Centers for Disease Control and Prevention (CDC) in 2000 as a health scientist in the National Center on Birth Defects and Developmental Disabilities. In 2004, Cyril joined the Office of the Associate Director for Science (OADS). Since 2010, Cyril has been the deputy director for the Office of Science Quality at OADS. As deputy, she is responsible for overseeing the CDC Technology Transfer Office and coordinating SBIR Program. Cyril also serves as the agency’s senior advisor for extramural research responsible for developing policies and practices that assure the transparency, integrity, and credibility of CDC’s extramural research programs.
John Doucet, Ph.D., received a Bachelor of Science in Biomedical Engineering from Syracuse University in 1987 and a doctoral degree in Neuroscience from Syracuse University in 1995. He then joined the Department of Otolaryngology at Johns Hopkins University as a postdoctoral fellow, where he studied the physiology and anatomy of brain circuits that underlie sound localization and the sensitivity of ears. He continued this work at Johns Hopkins University and was promoted to research associate in 1998 and assistant professor in 2003. Doucet joined the U.S. Food and Drug Administration in 2008 and has worked as a premarket scientific reviewer in the Center for Devices and Radiological Health, Office of Device Evaluation. He has reviewed a variety of premarket applications that describe neurosurgical, neurodiagnostic and neurotherapeutic devices.
J.P. Kim serves as director and policy officer of the Division of Extramural Inventions and Technology Resources under the Office of Policy for Extramural Research Administration (OPERA) within the NIH’s Office of Extramural Research, with a focus on providing expert policy guidance and support on invention reporting, material and data resource sharing and associated intellectual property matters. Prior to joining OPERA, Kim worked for 10 years in the Office of Technology Transfer in NIH’s Office of Intramural Research as a technology licensing specialist and patent advisor for advancing NIH inventions into commercial products. His experience also includes over 10 years in the private sector at intellectual property law firms, which included work on domestic and international patent and trademark prosecution, litigation and related work with the U.S. International Trade Commission. Kim also has academic research experience as a cancer researcher at the George Washington University School of Medicine and the Health Sciences, as well as commercial research experience at several biotechnology firms. Kim has attended Georgetown University, American University, George Washington University, the University of Maryland and Johns Hopkins University, where he earned degrees in the areas of law, international business and marketing, biotechnology, liberal studies and social/public policy, health policy, zoology, chemistry and psychology, as well as additional graduate work in genetics, the nonprofit sector, international trade, international law, and European Union law. He is a registered U.S. Patent Attorney and is admitted to the Maryland Courts and numerous federal courts, including the U.S. Court of International Trade, the Court of Appeals for the Federal Circuit, and the U.S. Supreme Court.